Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration

Journal of Dental Research

Volumn 87, Issue 9, 2008, Pages 845-849

  Koh, J T ^a,b   Zhao, Z ^a   Wang, Z ^c   Lewis, I S ^a   Krebsbach, P H ^c   Franceschi, R T ^a,d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b Chonnam National University   (South Korea)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus; Bone morphogenetic proteins; Bone regeneration; Cranial defect; Gene therapy; Heterodimer

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; GELATIN SPONGE; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ANIMAL; ARTICLE; BIODEGRADABLE IMPLANT; BONE DEVELOPMENT; BONE REGENERATION; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CRANIOTOMY; CYTOLOGY; FIBROBLAST; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MYOBLAST; PHYSIOLOGY; TISSUE REGENERATION; TISSUE SCAFFOLD; TRANSGENE; WOUND HEALING;

ABSORBABLE IMPLANTS; ADENOVIRIDAE; ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CELL DIFFERENTIATION; CELLS, CULTURED; CRANIOTOMY; FIBROBLASTS; GELATIN SPONGE, ABSORBABLE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GUIDED TISSUE REGENERATION; MICE; MICE, INBRED C57BL; MYOBLASTS; OSTEOGENESIS; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES; WOUND HEALING;

EID: 52649100956     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910808700906     Document Type: Article

References (33)

1. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K, Kato M, et al. (2001). Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction, J Cell Sci 114(Pt 8):1483-1489,
2. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, et al. (1995). Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210:670-677.
3. Cochran DL, Jones AA, Lilly LC, Piorellini JP, Howell H (2000). Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans. J Periodontal 71:1241 -1257.
4. Franceschi RT (2005), Biological approaches to bone regeneration by gene therapy. J Dent Res 84:10934103.
5. Franceschi RT, Yang S, Rutherford RB, Krebsbach PH, Zhao M, Wang D (2004). Gene therapy approaches for bone regeneration. Cells Tissues Organs 176:95408.
6. Geesink RG, Hoefnagels NH, Bulstra SK (1999). Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81:710418.
7. Giannobile WV, Ryan S, Shih MS, Su DL, Kaplan PL, Chan TC (1998). Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. J Periodontal 69:129-137.
8. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, et al. (2002). Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84(A):2123-2134.
9. Hassel S, Schmitt S, Hartung A, Roth M, Nohe A, Petersen N, et al. (2003). Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am 85(A)(Suppl 3):44-51.
10. Hogan BL (1996). Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
11. Huang YC, Kaigler D, Rice KG, Krebsbach PH, Mooney DJ (2005). Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J Bone Miner Res 20:848-857.
12. King GN, King N, Cruchley AT, Wozney JM, Hughes FJ (1997). Recom-binant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. J Dent Re 76:1460-1470.
13. Kirker-Head CA (2000). Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 43:65-92.
14. Koh JT, Ge C, Zhao M, Wang Z, Krebsbaeh PH, Zhao Z, et al. (2006). Use of a stringent dimerizer-rcgulated gene expression system for controlled BMP2 delivery. Mol Ther 14:684-691.
15. Krebsbaeh PH, Gu K, Franceschi RT, Rutherford RB (2000). Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 11:1201-1210.
16. Lieberman JR. Le LQ, Wu L, Finerman GA, Berk A, Witte ON, et al. (1998). Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16:330-339.
17. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, et al. (1999). The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81:905-917.
18. Manolagas SC, Burton DW, Deltas LJ (1981). 1,25-Dihydroxyvitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem 256:7115-7117.
19. Nakamura K, Shirai T, Morishita S, Uchida S, Saeki-Miura K, Makishima F (1999). p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp Cell Res 250:351-363.
20. Nishitoh H, Ichijo H, Kimura M, Matsumoto T, Makishima F, Yamaguchi A, et al. (1996). Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 271:21345-21352.
21. Nohe A, Keating E, Knaus P, Petersen NO (2004). Signal transduction of bone morphogenetic protein receptors. Cell Signal 16:291-299.
22. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. (2002). Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751-759.
23. Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT (2006). BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Pes 21:637-646.
24. Riew KD, Wright NM, Cheng S, Avioli LV, Lou J (1998). Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 63:357-360.
25. Rutherford RB, Moalli M, Franceschi RT, Wang D, Gu K, Krebsbaeh PH (2002). Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng 8:441-452.
26. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, et al. (1994). Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269:16985-16988.
27. Winn SR, Hu Y, Sfeir C, Hollinger JO (2000). Gene therapy approaches for modulating bone regeneration. Adv Drug Deliv Rev 42:121-138.
28. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, et at (1995). Osteogenic protein-1 binds to aetivin type Il receptors and induces certain activin-like effects. J Cell Biol 130:217-226.
29. Zhao M, Zhao Z, Koh JT, Jin T, Franceschi RT (2005). Combinatorial gene therapy for bone regeneration: cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 95:1-16.
30. Zhao Z, Zhao M, Xiao G, Franceschi RT (2005). Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 12:247-253.
31. Zhao Z, Wang Z, Ge C, Krebsbaeh P, Franceschi RT (2007). Healing cranial defects with AdRunx2-transduced marrow stromal cells. J Dent Res 86:1207-1211.
32. Zhu W, Rawlins BA, Boachie-Adjei O, Myers ER, Arimizu J, Choi E, et al. (2004). Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19:2021-2032.
33. Zhu W, Kim J, Cheng C, Rawlins BA, Boaehie-Adjei O, Crystal RG, el al. (2006). Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39:61-71.